TABLE 3.
Univariate and multivariate analyses of DRGS, and clinical and pathologic factors.
| Characteristic | Training cohort GSE39582 | Validation-1 TCGA | Validation-2 (GSE14333,GSE33113,GSE37892, and GSE39084) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | |
| DRGS | 2.40 (1.67–3.44) | 9.40E-07 | 1.80 (1.22–2.64) | 0.0028 | 2.20 (1.38–3.49) | <0.001 | 1.85 (1.13–3.02) | 0.015 | 2.12 (1.40–3.21) | <0.001 | 1.75 (1.15–2.65) | 0.0085 |
| Gender | 1.21 (0.89–1.64) | 0.21 | - | - | 1.25 (0.82–1.89) | 0.3 | - | - | 1.06 (0.74–1.50) | 0.77 | - | - |
| Age | 1.00 (0.99–1.01) | 1 | - | - | 0.99 (0.97–1.00) | 0.16 | - | - | 0.99 (0.98–1.00) | 0.16 | - | - |
| Tumor location | 1.27 (0.92–1.74) | 0.14 | - | - | 0.88 (0.58–1.33) | 0.55 | - | - | 1.19 (0.81–1.75) | 0.38 | - | - |
| MMR status | 2.76 (1.46–5.24) | 0.0012 | 1.94 (0.97–3.87) | 0.062 | 0.94 (0.61–1.45) | 0.77 | - | - | 1.74 (0.80–3.77) | 0.15 | - | - |
| CIMP status | 0.71 (0.44–1.15) | 0.16 | - | - | - | - | - | - | 0.82 (0.39–1.72) | 0.6 | - | - |
| CIN status | 1.09 (0.70–1.71) | 0.71 | - | - | - | - | - | - | - | - | - | - |
| TP53 mutation | 1.41 (0.99–2.03) | 0.059 | - | - | - | - | - | - | 1.59 (0.70–3.61) | 0.26 | - | - |
| KRAS mutation | 1.40 (1.03–1.91) | 0.031 | 1.16 (0.84–1.59) | 0.37 | 0.76 (0.31–1.83) | 0.54 | - | - | 1.25 (0.65–2.38) | 0.5 | - | - |
| BRAF mutation | 0.96 (0.54–1.69) | 0.88 | NA | - | 0.00 (0.00–Inf) | 0.46 | - | - | 1.61 (0.77–3.37) | 0.2 | - | - |